https://www.selleckchem.com/products/ri-1.html
INTRODUCTION Mepolizumab was the first licensed anti-IL5 mAb for severe eosinophilic asthma (SEA). To date there is little data to confirm its efficacy in the real-world setting or assessment of baseline characteristics associated with response. METHODS We conducted a retrospective review of all patients who received at least 16 weeks of treatment with mepolizumab (100mg sc) for SEA at our regional asthma centre in the UK. Clinical data was collected at each 4-weekly visit. At 16, 24 and 52 weeks, patients were classified as 'responders' o
Gefällt mir
Kommentar
Teilen
